**Alnylam Pharmaceuticals Experiences High Options Volatility**
Investors in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) should take note of significant activity in the options market, particularly the July 17, 2026, $210 Call, which has exhibited some of the highest implied volatility among equity options today. High implied volatility often indicates that the market anticipates significant price movement, suggesting a potential event could be on the horizon that might lead to sharp gains or losses.
In terms of analyst sentiment, Alnylam holds a Zacks Rank of #3 (Hold) in the Medical – Biomedical and Genetics sector. Over the past month, two analysts have raised their earnings estimates for the current quarter, increasing the Zacks Consensus Estimate from $2.01 to $2.10 per share, while three analysts have lowered their estimates. This mixed sentiment, coupled with heightened options volatility, may signify opportunities for traders anticipating a notable price shift.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
